DAWN FY 2025 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$158M+20.6% YoY

Gross Profit

$141M89.1% margin

Operating Income

-$128M-80.8% margin

Net Income

-$107M-67.8% margin

EPS (Diluted)

$-1.04

Cash Flow

Operating Cash Flow

-$104M

Free Cash Flow

-$104M

Stock-Based Comp.

$44M

Balance Sheet

Total Assets

$508M

Total Liabilities

$67M

Stockholders' Equity

$441M

Cash & Equivalents

$197M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$158M	$131M	+20.6%
Gross Profit	$141M	$126M	+12.0%
Operating Income	-$128M	-$217M	+41.2%
Net Income	-$107M	-$95M	-12.4%